Skip to main content
Top
Published in: Infection 4/2013

01-08-2013 | Brief Report

Measuring synovial fluid procalcitonin levels in distinguishing cases of septic arthritis, including prosthetic joints, from other causes of arthritis and aseptic loosening

Authors: K. Saeed, M. Dryden, A. Sitjar, G. White

Published in: Infection | Issue 4/2013

Login to get access

Abstract

Objectives

Differentiating septic arthritis from non-septic arthritis can be challenging as the clinical pictures are similar and an efficacious diagnostic test is not yet available. Our objectives in this study were to establish if procalcitonin (PCT) could be reproducibly measured from synovial fluid, if there is a difference in synovial procalcitonin values between patients with septic and non-septic arthritis, respectively, including those with implants and to determine cut-off levels that could be used as a practical tool in the management of these conditions.

Methods

Using a standard serum assay, synovial fluid PCT levels were measured retrospectively in 26 septic and 50 non-septic predefined arthritis cases. The reproducibility of synovial PCT was also assessed at various concentrations.

Results

Synovial PCT can be measured and is reproducible. In this cohort, statistically significant higher synovial PCT levels were found in cases of septic arthritis than in non-septic arthritis. Sensitivities, specificities and positive and negative predictive values varied at different cut-off levels.

Conclusion

The test could be added to other microbiological and biochemical tests and may be used to supplement other clinical, radiological and laboratory findings in the assessment of patients with acute painful joints. In our cohort, findings of very high synovial PCT levels supported an infection process, including in prosthesis-related infections. The high negative predictive value of low synovial PCT levels could exclude infection in both native and prosthetic joints. Larger prospective studies are needed to further validate these results and to examine the cost effectiveness of synovial PCT.
Literature
1.
go back to reference Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA. 2007;297:1478–88.PubMedCrossRef Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA. 2007;297:1478–88.PubMedCrossRef
2.
go back to reference Ma L, Cranney A, Holroyd-Leduc JM. Acute monoarthritis: what is the cause of my patient’s painful swollen joint? Can Med Assoc J. 2009;180:59–65.CrossRef Ma L, Cranney A, Holroyd-Leduc JM. Acute monoarthritis: what is the cause of my patient’s painful swollen joint? Can Med Assoc J. 2009;180:59–65.CrossRef
3.
go back to reference Saeed K, Ahmad N, Pallett A, Guiver M, Marsh P. Specific staphylococcal polymerase chain reaction can be a complementary tool for identifying causative organisms and guiding antibiotic management in orthopaedic infections. Curr Ortho Pract. 2010;21:628–31.CrossRef Saeed K, Ahmad N, Pallett A, Guiver M, Marsh P. Specific staphylococcal polymerase chain reaction can be a complementary tool for identifying causative organisms and guiding antibiotic management in orthopaedic infections. Curr Ortho Pract. 2010;21:628–31.CrossRef
4.
go back to reference Christ-Crain M, Müller B. Procalcitonin in bacterial infections—hype, hope, more or less? Swiss Med Wkly. 2005;135:451–60.PubMed Christ-Crain M, Müller B. Procalcitonin in bacterial infections—hype, hope, more or less? Swiss Med Wkly. 2005;135:451–60.PubMed
5.
go back to reference Giamarellos-Bourboulis EJ, Mega A, Grecka P. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med. 2002;28:1351–6.PubMedCrossRef Giamarellos-Bourboulis EJ, Mega A, Grecka P. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med. 2002;28:1351–6.PubMedCrossRef
6.
go back to reference Das RR. Should procalcitonin be used as a routine biomarker of bacterial infection? Infection. 2012;40:713–4.PubMedCrossRef Das RR. Should procalcitonin be used as a routine biomarker of bacterial infection? Infection. 2012;40:713–4.PubMedCrossRef
7.
go back to reference Lipinska-Gediga M, Mierzchala M, Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection. 2012;40:303–9.PubMedCrossRef Lipinska-Gediga M, Mierzchala M, Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection. 2012;40:303–9.PubMedCrossRef
8.
go back to reference Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection. 2011;39:411–7.PubMedCrossRef Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection. 2011;39:411–7.PubMedCrossRef
9.
go back to reference Stojanovic K, Steichen O, Lionnet F, Bachmeyer C, Lecomte I, Avellino V, Grateau G, Girot R, Lefevre G. Is procalcitonin a marker of invasive bacterial infection in acute sickle-cell vaso-occlusive crisis? Infection. 2011;39:41–5.CrossRef Stojanovic K, Steichen O, Lionnet F, Bachmeyer C, Lecomte I, Avellino V, Grateau G, Girot R, Lefevre G. Is procalcitonin a marker of invasive bacterial infection in acute sickle-cell vaso-occlusive crisis? Infection. 2011;39:41–5.CrossRef
10.
go back to reference Saeed K, Dryden M, Bourne S, Paget C, Proud A. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. J Hosp Infect. 2011;78:289–92.PubMedCrossRef Saeed K, Dryden M, Bourne S, Paget C, Proud A. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. J Hosp Infect. 2011;78:289–92.PubMedCrossRef
11.
go back to reference Hügle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, Daikeler T. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol. 2008;26:453–6. Hügle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, Daikeler T. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol. 2008;26:453–6.
12.
go back to reference Martinot M, Sordet C, Soubrier M. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol. 2005;23:303–10.PubMed Martinot M, Sordet C, Soubrier M. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol. 2005;23:303–10.PubMed
13.
go back to reference Streit G, Alber D, Toubin MM, Toussirot E, Wendling D. Procalcitonin, C-reactive protein, and complement-3a assays in synovial fluid for diagnosing septic arthritis: Preliminary results. Joint Bone Spine 2008;75:238–9. Streit G, Alber D, Toubin MM, Toussirot E, Wendling D. Procalcitonin, C-reactive protein, and complement-3a assays in synovial fluid for diagnosing septic arthritis: Preliminary results. Joint Bone Spine 2008;75:238–9.
14.
go back to reference Söderquist B, Jones I, Fredlund H, Vikerfors T. Bacterial or crystal-associated arthritis? Discriminating ability of serum inflammatory markers. Scand J Infect Dis 1998;30:591–6. Söderquist B, Jones I, Fredlund H, Vikerfors T. Bacterial or crystal-associated arthritis? Discriminating ability of serum inflammatory markers. Scand J Infect Dis 1998;30:591–6.
15.
go back to reference Bottner F, Wegner A, Winkelmann W, Becker K, Erren M, Gotze C. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br. 2007;89:94–9.PubMed Bottner F, Wegner A, Winkelmann W, Becker K, Erren M, Gotze C. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br. 2007;89:94–9.PubMed
16.
go back to reference Worthington T, Dunlop D, Casey A, Lambert R, Luscombe J, Elliott T. Serum procalcitonin, interleukin-6, soluble intercellular adhesin molecule-1 and IgG to short-chain exocellular lipoteichoic acid as predictors of infection in total joint prosthesis revision. Br J Biomed Sci. 2010;67:71–6.PubMed Worthington T, Dunlop D, Casey A, Lambert R, Luscombe J, Elliott T. Serum procalcitonin, interleukin-6, soluble intercellular adhesin molecule-1 and IgG to short-chain exocellular lipoteichoic acid as predictors of infection in total joint prosthesis revision. Br J Biomed Sci. 2010;67:71–6.PubMed
17.
go back to reference Randau T, Wimmer M, Kuberra D, Reichert B, Stoffel-Wagner B, Wirtzl D-C, Gravius S. Detection of periprosthetic joint infections: blood infection markers in patients undergoing revision arthroplasty. Eur Cells Mater. 2011;21:36. Randau T, Wimmer M, Kuberra D, Reichert B, Stoffel-Wagner B, Wirtzl D-C, Gravius S. Detection of periprosthetic joint infections: blood infection markers in patients undergoing revision arthroplasty. Eur Cells Mater. 2011;21:36.
Metadata
Title
Measuring synovial fluid procalcitonin levels in distinguishing cases of septic arthritis, including prosthetic joints, from other causes of arthritis and aseptic loosening
Authors
K. Saeed
M. Dryden
A. Sitjar
G. White
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0467-2

Other articles of this Issue 4/2013

Infection 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.